The depletion of serine beta‐lactamase‐like protein (LACTB) ameliorates metabolic dysfunction–associated steatotic liver disease by reducing ubiquitin‐mediated degradation of carnitine palmitoyltransferase 2
Authors:
Open Access
- 13 January 2026
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (4) , 2962-2977
Abstract
Aims: Metabolic dysfunction–associated steatotic liver disease (MASLD) represents one of the most common chronic liver disorders worldwide, and its incidence continues to rise each year. Serine β‐lactamase‐like protein (LACTB) is a serine protease that plays a crucial role in lipid metabolism and hepatocellular carcinoma, but its function in MASLD remains unclear. Therefore, the study aims to elucidate the effect and mechanism of LACTB in the progression of MASLD. Materials and methods: The expression of LACTB in liver tissues from MASLD patients and high‐fat diet (HFD) fed mice was assessed. Both in vivo and in vitro models were established to examine the role and molecular mechanisms of LACTB in MASLD. Results: LACTB protein levels were upregulated in the liver tissues from MASLD patients and HFD‐fed mice. LACTB overexpression exacerbated hepatic steatosis, insulin resistance, and inflammation in HFD‐fed mice. Conversely, LACTB knockdown improved these phenotypes. Mechanistically, LACTB interacted with CPT2 and promoted its ubiquitin‐mediated degradation. The effect of LACTB in hepatocellular lipid metabolism was dependent on CPT2. Conclusions: Our findings indicate that LACTB is a novel regulatory factor in MASLD by influencing the ubiquitin‐mediated degradation of CPT2 to participate in disease progression. These findings may provide a novel potential therapeutic strategy for MASLD.Keywords
Funding Information
- National Natural Science Foundation of China (82270599)
This publication has 44 references indexed in Scilit:
- Lactamase β reprograms lipid metabolism to inhibit the progression of endometrial cancer through attenuating MDM2-mediated p53 ubiquitination and degradationArchives of Biochemistry and Biophysics, 2024
- Human genetics identify convergent signals in mitochondrial LACTB-mediated lipid metabolism in cardiovascular-kidney-metabolic syndromeCell Metabolism, 2024
- SNPs Give LACTB Oncogene‐Like Functions and Prompt Tumor Progression via Dual‐Regulating p53Advanced Science, 2024
- Metabolic enzyme Suclg2 maintains tolerogenicity of regulatory dendritic cells diffDCs by suppressing Lactb succinylationJournal of Autoimmunity, 2023
- Impact of NAFLD and its pharmacotherapy on lipid profile and CVDAtherosclerosis, 2022
- Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancerCell Metabolism, 2022
- Mitochondrial protease ClpP supplementation ameliorates diet-induced NASH in miceJournal of Hepatology, 2022
- LACTB suppresses melanoma progression by attenuating PP1A and YAP interactionCancer Letters, 2021
- LACTB promotes metastasis of nasopharyngeal carcinoma via activation of ERBB3/EGFR-ERK signaling resulting in unfavorable patient survivalCancer Letters, 2021
- Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver diseaseCellular and Molecular Life Sciences, 2018